Modifying the Tumor Microenvironment to Make Treatment More Effective
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?
Researchers are studying whether peritoneal washing after pancreatic cancer surgery decreases recurrence of the cancer by removing stray cancer cells.
Researchers are looking at losartan and nivolumab combined with standard protocol of chemotherapy and radiation to see either drug or a combination is more effective.
This trial remains active but is not recruiting at this time. A pancreatectomy or Whipple procedure can remove a patient’s main tumor, but post-surgical testing of lymph nodes and the edges of the tissue left after surgery often finds cancer cells. These patients are at high risk of recurrence of the disease. Researchers are trying…
Researchers are creating personalized vaccines to stimulate a pancreatic cancer patient’s immune system after surgery and chemotherapy.